A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Save time and jump to the most important pieces.
4 - NANOVIRICIDES, INC. (0001379006) (Issuer)
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications.There are several viruses that continue to cause epidemics in humans; seasonal epidemics with Influenza, RSV, and SARS-CoV-2 (COVID) are occurring every year. The potential for severe Bird Flu pandemic, that may even be worse than the COVID-19 outbreak, is increasing every year as the virus spreads further into mammals and mutates more, according to experts.
SHELTON, CT / ACCESSWIRE / November 15, 2024 / SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).We reported that, as of September 30, 2024, we had cash and cash equivalent current assets balance of approximately $3.87 Million. In addition, we reported approximately $7.36 Million in Net Property and Equipment (P&E) assets (after de
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a corporate update at the Spartan Capital Investors Conference on Monday, November 4, 2024 (today) at 9:45 am. The Conference will be held at the Pierre Hotel in New York City.EventThe Spartan Capital Investors Conference 2024Day & DateMonday, November 4, 2024LocationThe Pierre Hotel, New York, NY, USA.Talk TitleRevolutionizing Antiviral Treatments, Phase 2-Ready, Broad-Spectrum Lead Drug NV-387 Addresses a $2.5 to $4
SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a talk at the PODD Conference on Monday, October 28th, 2024 at 345pm. The PODD Conference will be held at the Westin Boston Seaport District, MA on October 28 and 29, 2024.EventThe Partnership Opportunities in Drug Delivery (PODD) Conference, 2024Day & DateMonday, October 28, 2024LocationThe Westin Boston Seaport District Hotel, Boston, MA, USA.Talk TitleRevolutionizing Antiviral Treatments, Phase 2-Ready, Ora
SC 13G/A - NANOVIRICIDES, INC. (0001379006) (Subject)
10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)
DEF 14A - NANOVIRICIDES, INC. (0001379006) (Filer)
10-K - NANOVIRICIDES, INC. (0001379006) (Filer)